Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.78 |
| ▸ | CTSK | P43235 | 11/20 | 0.75 |
| ▸ | CTSL | P07711 | 5/20 | 0.70 |
| ▸ | CTSS | P25774 | 3/20 | 0.70 |
| ▸ | CTSB | P07858 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8823914 | 1.00 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL29308017 | 1.00 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL9338295 | 1.00 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL8585293 | 0.95 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL8584264 | 0.95 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL8585289 | 0.93 | CAPN1 (0.69) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL8584262 | 0.93 | CAPN1 (0.69) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL7612532 | 0.91 | CTSK (0.71) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL7612544 | 0.91 | CTSK (0.71) | CAPN1CTSKCTSLCTSSCTSB | |
| SCHEMBL8823936 | 0.91 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
| EP-2697246-B1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-03-07 | — | — | EP | disclosed |
| US-8273403-B2 | Generation of surface coating diversity | BIO-LAYER PTY LTD. (AU) | 2012-09-25 | — | — | US | disclosed |
| EP-1534755-B1 | GENERATION OF SURFACE COATING DIVERSITY | BIO LAYER PTY LTD (AU) | 2011-10-12 | — | — | EP | disclosed |
| US-20060083858-A1 | Generation of surface coating diversity | ANTEO TECHNOLOGIES PTY LTD (AU) | 2006-04-20 | — | — | US | disclosed |
| EP-1534755-A4 | GENERATION OF SURFACE COATING DIVERSITY | BIO LAYER PTY LTD (AU) | 2005-08-17 | — | — | EP | disclosed |
| EP-1534755-A1 | GENERATION OF SURFACE COATING DIVERSITY | Bio-Layer Pty Limited (AU) | 2005-06-01 | — | — | EP | disclosed |
| WO-2003095494-A1 | GENERATION OF SURFACE COATING DIVERSITY | BIO-LAYER PTY LIMITED (AU) | 2003-11-20 | — | — | WO | disclosed |
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0633905-A1 | BIODEGRADABLE POLYCARBONATES AND THEIR USE AS DRUG CARRIERS | SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H. (AT) | 1995-01-18 | — | — | EP | disclosed |
| EP-0249434-B1 | Peptide derivatives and processes for their preparation | VYZK USTAV FARM BIOCHEM SP (CZ) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993020126-A1 | BIODEGRADABLE POLYCARBONATES AND THEIR USE AS DRUG CARRIERS | SANDOZ LTD. (CH) | 1993-10-14 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4898930-A | Peptide derivatives and processes for their preparation | SPOFA, SPOJENE PODNIKY PRO (CS) | 1990-02-06 | — | — | US | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0249434-A2 | Peptide derivatives and processes for their preparation | Vyzkumny ustav pro farmacii a biochemii (CZ) | 1987-12-16 | — | — | EP | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4418012-A | Leucylalany-arginine derivative | TORII & CO. LTD. (JP) | 1983-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | CAPN1 3410/4885CTSK 528/4885CTSL 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.